Skip to main content
ARDELYX, INC. logo

ARDELYX, INC. — Investor Relations & Filings

Ticker · ARDX ISIN · US0396971071 LEI · 549300F542QR4SXHCY32 US Manufacturing
Open in API
Filings indexed 1,078 across all filing types
Latest filing 2016-08-19 Regulatory Filings
Country US United States of America
Listing US ARDX

About ARDELYX, INC.

https://www.ardelyx.com/

Ardelyx, Inc. is a biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines to address unmet medical needs. The company's primary therapeutic areas of focus are cardiorenal and gastrointestinal diseases. Its key commercial product is XPHOZAH® (tenapanor), a novel mechanism therapy for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Ardelyx also develops treatments for Irritable Bowel Syndrome with Constipation (IBS-C), aiming to advance patient care through its portfolio of innovative therapies.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings
2016-08-19 English
FORM S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 registration statement filed with the SEC, which is a registration statement used for securities offerings under the Securities Act of 1933. It includes details about the offering of common stock, selling stockholders, use of proceeds, risk factors, and other related information. This type of filing is related to capital raising activities and financing. It is not an annual report, earnings release, or any other financial report but specifically a registration statement for securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not RPA or RNS.
2016-08-11 English
FORM 10-Q
Interim / Quarterly Report Q2 2016
2016-08-08 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company announced its financial results for the quarter ended June 30, 2016, and that the full text of the press release is furnished as an exhibit. The document itself is only 2700 characters, which is quite short and primarily serves as an announcement of the earnings release rather than containing detailed financial statements or analysis. According to the rules, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER). The document is not the full quarterly report (IR) but an announcement of results. Therefore, the correct classification is Earnings Release (ER) with high confidence.
2016-08-08 English
Regulatory Filings 2016
Regulatory Filings
2016-08-01 English
SCHEDULE 13D - AMENDMENT #4
Major Shareholding Notification
2016-07-28 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.